AUTO1 Group Reports First Quarter 2025 Earnings
Key Financial Results
Revenue: €1.94b (up 34% from 1Q 2024).
Net income: €29.9m (up from €3.46m loss in 1Q 2024).
Profit margin: 1.5% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue.
Our free stock report includes 3 warning signs investors should be aware of before investing in AUTO1 Group. Read for free now.
XTRA:AG1 Earnings and Revenue Growth May 8th 2025
All figures shown in the chart above are for the trailing 12 month (TTM) period
AUTO1 Group Earnings Insights
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Specialty Retail industry in Germany.
Performance of the German Specialty Retail industry.
The company's shares are down 9.0% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with AUTO1 Group (at least 2 which are a bit unpleasant), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
‘What Tariffs? Who Cares?' as Inflation Data Ignites Risk Assets
(Bloomberg) -- Global investors dived in the riskiest assets after a benign US inflation report dispelled fears of stagflation and lifted a roadblock for the Federal Reserve to cut interest rates. Stocks jumped to fresh record highs, and small-cap stocks, emerging-markets and semiconductors extended a rally. Measures of implied volatility plunged even as President Donald Trump tariffs threaten to disrupt global trade. The crypto rally has also broadened, with Ether notching a 55% jump in the past month. Meme stocks are seeing a resurgence in popularity. Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' New York Warns of $34 Billion Budget Hole, Biggest Since 2009 Crisis Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets The moves underscore the roaring optimism that's been unleashed in the past few months. Fears over a looming trade war, which sparked a selloff in April, have given way to confidence that the economy can keep powering ahead. The latest move has been powered by renewed hopes over imminent rate cuts in the US. 'The mood is surprisingly bullish, it's almost like 'what tariffs, who cares?' said Neil Birrell, chief investment officer at Premier Miton Investors. 'There's this detachment from economic reality on what's happening and there's a wave of either optimism or exuberance in equity markets.' Swaps are now pricing in about a 90% chance of a quarter-point move in September, while some traders loading up on bets on an even bigger move. In an interview Tuesday, Treasury Secretary Scott Bessent suggested that the Fed ought to be open to a bigger, 50 basis-point cut next month. Against that backdrop, the S&P 500 Index is back at record highs as solid corporate earnings highlighted a muted impact from sweeping tariffs. The benchmark has surged almost 30% since a low in April — when Trump's trade shock sparked a flight from US assets. The gauge is also up nearly 12% since Trump won the election in November. In another sign of market confidence: volatility measures have collapsed. The VIX is the lowest since December, while the MOVE Index of bond-market volatility is at its most subdued level since 2022. A measure of implied price swings in FX markets is also at the lowest in a year. 'Do I see a lot of potential risks to dent some of the sentiment and expectations? I do. But I do not think the market is being irrational at this point in time. We could go a lot further before the market gets irrational,' Bernard Ahkong, CIO at UBS O'Connor Global Multi-Strategy Alpha, said in a Bloomberg TV interview. 'It's very expensive right now to be bearish.' In equity markets, sentiment has flipped from fears of a trade-induced recession in April to outright optimism around economic resilience, mild inflation and potential interest rate cuts. Renewed buzz around artificial intelligence has once again put the technology behemoths in the lead. The so-called Magnificent Seven group of tech stocks, which include Nvidia Corp. and Microsoft Corp., have rallied almost 50% since early April after sinking in the first quarter. Most of that is down to robust earnings, which allayed worries that the companies are overspending on AI. Megacap tech stocks almost single-handedly drove earnings growth in the second quarter, accounting for 90% of the overall increase in S&P 500 profits, according to an analysis by Deutsche Bank AG strategists. What Bloomberg Strategists Say 'It would be foolish to fight this stock market rally, even if the fundamental framework underpinning the market seems extremely flimsy. At some point, the rise in US long-end yields will damage equities, if they don't trip themselves up first, or we don't get another Trump curveball. But there's no need to prematurely trade that narrative.' — Mark Cudmore, Markets Live Executive Editor. Click here for the full analysis. The euphoria is even spreading to the riskiest corners of the US equity market. The Russell 2000 index of small-cap stocks — which tend to be more sensitive to interest rates than the large-cap cohort — is tracking a fourth straight month of gains. The erratic moves in stocks this year have caused a frenzy among Wall Street strategists, who broadly struggled to keep with the slump in April as well as the subsequent recovery. Some — such as Morgan Stanley's Michael Wilson and former Wells Fargo strategist Chris Harvey — were among the rare forecasters whose nerves of steel during the April rout proved right in the end. While Wilson warned that the S&P 500 faced further declines in the short term, he held on to his bullish 12-month target and, since May, has been advising clients to buy the dip. His peers at banks such as Goldman Sachs Group Inc. and Citigroup Inc. were less successful. They rushed to slash targets in the aftermath of the trade announcements, only to return to a bullish view as Trump paused the steep levies and earnings proved resilient. Now, Wall Street prognosticators are turning even more optimistic. Citigroup strategist Scott Chronert raised his year-end target for the S&P 500 again this month, partly as he expects tax cuts to offset the impact of tariffs. And while investors have matched that positive mood, positioning data show their equity allocation isn't stretched. In other markets, though, the recovery from April is less assured. US 10-year yields are within five basis points of levels seen at the end of March. Bloomberg's gauge of the dollar is still down more than 9% from its high before inauguration day. 'Rates are going to continue to price in further Fed rate cuts on the back of the increasing debate that we're likely see a 25 or 50 basis point move in September,' said Laura Cooper, head of macro credit and global investment strategist at Nuveen. 'The inflation print yesterday cleared the way for that debate to become a bit move lively.' --With assistance from Freya Jones and Alice Atkins. Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Dubai's Housing Boom Is Stoking Fears of Another Crash The Social Media Trend Machine Is Spitting Out Weirder and Weirder Results A $340 Million New York Office Makeover Is Converting Boardrooms to Bedrooms ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results
IRVINE, Calif., August 13, 2025--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (NASDAQ: SBC, "SBC Medical" or the "Company"), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025). Second Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $15 million, representing a 47% year-over-year decrease. Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.02 for the three months ended June 30, 2025, compared to $0.20 in the same period of 2024. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $15 million, representing a 46% year-over-year decrease. EBITDA margin1 was 35% for the second quarter of 2025, compared to 53% for second quarter of 2024. Return on equity, which is defined as net income attributable to the Company divided by the average of shareholder's equity as of June 30, 2025, was 4% representing a year-over-year decrease of 44 percentage points. Number of Franchise Locations2 was 259 as of June 30, 2025, representing an increase of 36 locations from June 30, 2024. Number of customers3 in the last twelve months ended June 30, 2025, was 6.31 million, representing a 14% year-over-year increase. Repeat rate for customers4 who visited franchisee's clinics twice or more was 72%. Total revenues were $91 million, representing a 16% year-over-year decrease. Income from operations was $39 million, representing a 25% year-over-year decrease. Net Income attributable to SBC Medical Group was $24 million, representing a 36% year-over-year decrease. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.23 for the six months ended June 30, 2025, compared to $0.40 in the same period of 2024. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $40 million, representing a 25% year-over-year decrease. EBITDA margin1 was 44% for the first half of 2025, compared to 50% for first half of 2024. Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, said, " As anticipated and signaled in our prior guidance, Q2 2025 reflected strategic shifts aimed to position SBC Medical for long-term competitiveness and scalability. Total revenue declined 18% year-over-year to $43 million, primarily due to the completed discontinuation of our staffing business, targeted divestitures to streamline our operations, and revision of fee structure. We are executing our strategic plan with precision, as evidenced by our network of 259 Franchise Locations as of June 30, 2025 and 6.31 million visits over the last twelve months, demonstrating a scale that is unmatched in Japan. Our high repeat rate underscores the strength of our Shonan Beauty Clinic brand. Japan's consumer discretionary market faces challenges, including restrained growth due to trade restrictions and cautious consumer spending. Despite these headwinds, we are successfully advancing key initiatives, including the acquisition of MB career lounge to enhance our management support services and the joining of JUN CLINIC to our network, which boasts a high average spend per customer. Looking ahead, we remain confident in our strategic roadmap, focused on optimizing our franchise model, capturing growth opportunities, transitioning to higher-margin models, and delivering lasting value to our shareholders." Second Quarter 2025 Financial Results Total revenues were $43 million, a decrease of 18% year-over-year, primarily due to a revised fee structure for franchising services implemented starting from April 2025, the discontinuation staffing services business, and divestiture of SNA and Kijimadaira, partially offset by growth in procurement, rental services, and other revenue streams. Net income attributable to SBC Medical Group for the three months ended June 30, 2025 was $2.5 million, compared to $18.5 million in the same period of 2024. The decrease was largely attributed to unfavorable changes in other income and expenses, primarily due to higher foreign exchange losses. EBITDA1 was $15 million, a decrease of 46% year-over-year, primarily due to lower revenue following the termination of the staffing services business, the deconsolidation of SNA and Kijimadaira, and revision of fee structure. Conference Call The Company will hold a conference call on Wednesday, August 13, 2025 at 8:30 am Eastern Time (or Wednesday, August 13, 2025 at 9:30 pm Japan Time) to discuss the financial results and take questions live. Please register in advance of the conference using the link provided It will automatically direct you to the registration page of "SBC Q2 2025 Financial Results Presentation.". Please follow the steps to enter your registration details, then click "Submit.". Upon registration, you will be able to access the dedicated Conference Call viewing site. In addition to viewing the conference call, this site provides access to information about the speakers as well as past investor relations materials. Starting 10 minutes before the conference call begins, you will be able to view the earnings presentation materials on the site. The materials will also be available for download. A replay of the conference call will be accessible until August 13, 2026. Additionally, the earnings release, accompanying slides, and an archived webcast of this conference call will be available at the Company's Investor Relations website at About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchise clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchise clinic customers, assistance with franchise employee housing rentals and facility rentals, construction and design of franchise clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchise clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchise clinic's customer rewards program (customer loyalty point program), and payment tools for the franchise clinics. For more information, visit Use of Non-GAAP Financial Measures The Company uses non-GAAP measures, such as EBITDA and EBITDA margin, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business. The Company believes that the non-GAAP financial measures provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The non-GAAP financial measures have limitations as analytical tools, and when assessing the Company's operating performance, cash flows or liquidity, investors should not consider them in isolation, or as a substitute for net loss, cash flows provided by operating activities or other consolidated statements of operations and cash flows data prepared in accordance with U.S. GAAP. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance. For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results." Forward Looking Statements This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company's beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's financial performance; growth in revenue and earnings; business prospects and opportunities; and capital deployment plans and liquidity. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at 1 EBITDA and EBITDA Margin are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section "Use of Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliations of GAAP and Non-GAAP Results." 2 The figures take into accounts of the franchising of SBC brand clinics, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC 3 The number of customers takes into account customers of SBC brand clinics, Rize Clinic and Gorilla Clinic, AHH Clinic but does not take account of customers of JUN CLINIC, but excluding free counseling. The applicable periods are from July 1, 2024, to June 30, 2025 4 The figures include franchising of SBC brand clinics, Rize Clinic, and Gorilla Clinic, but does not take account of customers of AHH clinics and JUN CLINIC excluding free counseling. The percentage of customers who visited our franchisee's clinics twice or more. SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 152,740,882 $ 125,044,092 Accounts receivable 2,350,368 1,413,433 Accounts receivable – related parties 48,920,843 28,846,680 Inventories 1,705,237 1,494,891 Finance lease receivables, current – related parties 9,128,931 5,992,585 Customer loans receivable, current 10,552,623 10,382,537 Prepaid expenses and other current assets 14,051,746 11,276,802 Other receivables – related parties 1,891,408 — Total current assets 241,342,038 184,451,020 Non-current assets: Property and equipment, net 8,058,016 8,771,902 Intangible assets, net 1,584,543 1,590,052 Long-term investments, net 3,593,087 3,049,972 Goodwill, net 5,011,511 4,613,784 Cryptocurrencies 535,882 — Finance lease receivables, non-current – related parties 13,197,979 8,397,582 Operating lease right-of-use assets 4,583,393 5,267,056 Finance lease right-of-use assets 516,932 — Deferred tax assets 2,343,302 9,798,071 Customer loans receivable, non-current 5,934,636 5,023,551 Long-term prepayments 1,755,292 1,745,801 Long-term investments in MCs – related parties 19,381,422 17,820,910 Other assets 7,461,224 15,553,453 Total non-current assets 73,957,219 81,632,134 Total assets $ 315,299,257 $ 266,083,154 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 16,290,206 $ 13,875,179 Accounts payable – related parties 3,245,989 659,044 Current portion of long-term loans 69,420 96,824 Notes and other payables, current – related parties 3,272,048 26,255 Advances from customers 512,123 820,898 Advances from customers – related parties 10,333,007 11,739,533 Income tax payable 14,133,163 18,705,851 Operating lease liabilities, current 3,623,871 4,341,522 Finance lease liabilities, current 161,340 — Accrued liabilities and other current liabilities 6,229,797 8,103,194 Due to related party 2,810,647 2,823,590 Total current liabilities 60,681,611 61,191,890 SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED BALANCE SHEETS — (Continued) June 30, 2025 December 31, 2024 Non-current liabilities: Long-term loans 7,031,506 6,502,682 Notes and other payables, non-current – related parties — 5,334 Deferred tax liabilities 353,517 926,023 Operating lease liabilities, non-current 1,208,516 1,241,526 Finance lease liabilities, non-current 164,721 — Other liabilities 1,206,815 1,193,541 Total non-current liabilities 9,965,075 9,869,106 Total liabilities 70,646,686 71,060,996 Stockholders' equity: Preferred stock ($0.0001 par value, 20,000,000 shares authorized; no shares issued and outstanding as of June 30, 2025 and December 31, 2024) — — Common stock ($0.0001 par value, 400,000,000 shares authorized, 103,881,251 and 103,020,816 shares issued, 103,098,442 and 102,750,816 shares outstanding as of June 30, 2025 and December 31, 2024, respectively) 10,388 10,302 Additional paid-in capital 72,196,114 62,513,923 Treasury stock (at cost, 782,809 and 270,000 shares as of June 30, 2025 and December 31, 2024, respectively) (5,115,262 ) (2,700,000 ) Retained earnings 213,423,693 189,463,007 Accumulated other comprehensive loss (35,922,942 ) (54,178,075 ) Total SBC Medical Group Holdings Incorporated stockholders' equity 244,591,991 195,109,157 Non-controlling interests 60,580 (86,999 ) Total stockholders' equity 244,652,571 195,022,158 Total liabilities and stockholders' equity $ 315,299,257 $ 266,083,154 The accompanying notes are an integral part of these unaudited consolidated financial MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS ANDCOMPREHENSIVE INCOME For the Three Months EndedJune 30, For the Six Months EndedJune 30, 2025 2024 2025 2024 Revenues, net – related parties $ 38,944,898 $ 51,039,038 $ 84,202,043 $ 101,509,245 Revenues, net 4,413,949 2,063,042 6,485,505 6,400,877 Total revenues, net 43,358,847 53,102,080 90,687,548 107,910,122 Cost of revenues (including cost of revenues from related parties of $4,669,602 and $3,616,103 for the three months ended June 30, 2025 and 2024, and $8,126,530 and $5,413,462 for the six months ended June 30, 2025 and 2024, respectively) 13,348,270 13,682,405 22,943,887 28,971,072 Gross profit 30,010,577 39,419,675 67,743,661 78,939,050 Operating expenses: Selling, general and administrative expenses (including selling, general and administrative expenses from related parties of $415,767 and nil for the three months ended June 30, 2025 and 2024, and $415,767 and nil for the six months ended June 30, 2025 and 2024, respectively) 15,456,385 12,129,115 28,987,395 27,187,605 Total operating expenses 15,456,385 12,129,115 28,987,395 27,187,605 Income from operations 14,554,192 27,290,560 38,756,266 51,751,445 Other income (expenses): Interest income 22,882 11,644 78,215 29,333 Interest expense (49,651 ) (7,424 ) (55,858 ) (10,432 ) Other income 33,771 306,291 185,099 655,972 Other expenses (1,132,465 ) (514,636 ) (2,829,724 ) (1,951,292 ) Gain on redemption of life insurance policies — — 8,746,138 — Change in fair value of cryptocurrencies 111,632 — 111,632 — Gain on disposal of subsidiary — — — 3,813,609 Total other income (expenses) (1,013,831 ) (204,125 ) 6,235,502 2,537,190 Income before income taxes 13,540,361 27,086,435 44,991,768 54,288,635 Income tax expense 11,100,509 8,529,110 21,059,966 16,981,094 Net income 2,439,852 18,557,325 23,931,802 37,307,541 Less: net income (loss) attributable to non-controlling interests (18,388 ) 72,917 (28,884 ) 65,381 Net income attributable to SBC Medical Group Holdings Incorporated $ 2,458,240 $ 18,484,408 $ 23,960,686 $ 37,242,160 Other comprehensive income (loss): Foreign currency translation adjustment $ 8,623,269 $ (9,046,549 ) $ 18,431,596 $ (19,240,401 ) Total comprehensive income 11,063,121 9,510,776 42,363,398 18,067,140 Less: comprehensive income (loss) attributable to non-controlling interests 184,411 22,000 147,579 (70,000 ) Comprehensive income attributable to SBC Medical Group Holdings Incorporated $ 10,878,710 $ 9,488,776 $ 42,215,819 $ 18,137,140 Net income per share attributable to SBC Medical Group Holdings Incorporated* Basic and diluted $ 0.02 $ 0.20 $ 0.23 $ 0.40 Weighted average shares outstanding* Basic and diluted 103,507,249 94,192,433 103,392,580 94,192,433 * Retrospectively restated for effect of reverse recapitalization on September 17, 2024. The accompanying notes are an integral part of these unaudited consolidated financial MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS For the Six Months Ended June 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net income $ 23,931,802 $ 37,307,541 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Depreciation and amortization expense 1,264,405 1,849,422 Non-cash lease expense 2,185,744 1,923,890 Provision for credit losses 283,752 62,804 Fair value change of long-term investments 384,523 1,045,557 Gain on disposal of subsidiary — (3,813,609 ) Gain on redemption of life insurance policies (8,746,138 ) — Gain on disposal of property and equipment (10,804 ) (902 ) Change in fair value of cryptocurrencies (111,632 ) — Deferred income taxes 7,452,983 (3,322,728 ) Changes in operating assets and liabilities: Accounts receivable (789,577 ) (1,423,412 ) Accounts receivable – related parties (17,039,113 ) 5,843,499 Inventories (717,972 ) 561,921 Finance lease receivables – related parties (6,482,967 ) (1,759,556 ) Customer loans receivable 8,081,703 7,521,267 Prepaid expenses and other current assets (1,349,225 ) (1,488,347 ) Long-term prepayments 211,988 (41,412 ) Other assets 85,907 (1,007,431 ) Accounts payable 1,165,217 (8,960,556 ) Accounts payable – related parties 2,455,865 — Notes and other payables – related parties (5,031,570 ) (5,101,368 ) Advances from customers (369,616 ) (755,977 ) Advances from customers – related parties (2,363,891 ) (4,663,233 ) Income tax payable (6,030,526 ) 5,462,133 Operating lease liabilities (2,275,398 ) (1,998,196 ) Accrued liabilities and other current liabilities (2,508,035 ) (4,444,172 ) Other liabilities (88,593 ) 77,625 NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES (6,411,168 ) 22,874,760 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (560,431 ) (1,565,333 ) Purchase of convertible note — (1,700,000 ) Prepayments for property and equipment (705,351 ) — Advances to related parties — (617,804 ) Payments made on behalf of related parties (1,836,541 ) (5,245,990 ) Purchase of long-term investments (652,555 ) — Purchase of cryptocurrencies (424,250 ) — Long-term loans to others (13,134 ) (62,489 ) Repayments from related parties 70,000 555,000 Repayments from others 56,307 44,748 Proceeds from redemption of life insurance policies 17,735,717 — Disposal of subsidiary, net of cash disposed of — (815,819 ) Proceeds from disposal of property and equipment 1,728,236 1,971 NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 15,397,998 (9,405,716 ) SBC MEDICAL GROUP HOLDINGS INCORPORATEDUNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS — (Continued) For the Six Months EndedJune 30, 2025 2024 CASH FLOWS FROM FINANCING ACTIVITIES Borrowings from related parties 15,000 — Repayments of long-term loans (74,256 ) (59,217 ) Repayments of finance lease liabilities (278,097 ) — Repayments to related parties (27,943 ) (50,124 ) Repurchase of common stock (2,415,262 ) — Deemed contribution in connection with price modification on disposal of property and equipment 9,682,277 — NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES 6,901,719 (109,341 ) Effect of exchange rate changes 11,808,241 (12,679,865 ) NET CHANGE IN CASH AND CASH EQUIVALENTS 27,696,790 679,838 CASH AND CASH EQUIVALENTS AS OF THE BEGINNING OF THE PERIOD 125,044,092 103,022,932 CASH AND CASH EQUIVALENTS AS OF THE END OF THE PERIOD $ 152,740,882 $ 103,702,770 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for interest expense $ 55,858 $ 10,432 Cash paid for income taxes, net $ 19,637,454 $ 16,191,178 NON-CASH INVESTING AND FINANCING ACTIVITIES Property and equipment transferred from long-term prepayments $ 246,188 $ — Operating lease right-of-use assets obtained in exchange for operating lease liabilities $ 104,437 $ — Finance lease right-of-use assets obtained in exchange for finance lease liabilities $ 612,466 $ — Remeasurement of operating lease liabilities and right-of-use assets due to lease modifications $ 1,160,680 $ 1,376,034 Payables to related parties in connection with loan services provided $ 8,175,342 $ 16,085,387 Issuance of common stock as incentive shares $ 86 $ — The accompanying notes are an integral part of these unaudited consolidated financial OF GAAP TO NON-GAAP FINANCIAL MEASURES SBC MEDICAL GROUP HOLDINGS INCORPORATEDUnaudited Reconciliations of GAAP and Non-GAAP Results For the Three Months EndedJune 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Total revenues, net $ 43,358,847 $ 53,102,080 $ 90,687,548 107,910,122 Income from operations 14,554,192 27,290,560 38,756,266 51,751,445 Depreciation and amortization expense 636,101 830,945 1,264,405 1,849,422 EBITDA 15,190,293 28,121,505 40,020,671 53,600,867 EBITDA margin 35 % 53 % 44 % 50 % The accompanying notes are an integral part of these unaudited consolidated financial statements. View source version on Contacts In Asia:SBC Medical Group Holdings IncorporatedHikaru Fukui / Head of Investor RelationsE-mail: ir@ In the US:ICR LLCBill Zima / Managing PartnerEmail: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
GE Appliances to invest over $3 billion in US manufacturing push
(Reuters) -Haier-owned GE Appliances said on Wednesday it plans to invest more than $3 billion over five years in its U.S. operations and workforce following the Trump administration's tariff policies aimed at boosting domestic manufacturing. Global firms have been increasing their investments and presence in the United States after President Donald Trump pushed companies across sectors, including Apple and Ford, to produce goods within the country and generate jobs. The GE Appliances investment will create 1,000 jobs in five states and is aimed at expanding the company's air conditioning and water heating portfolio, increasing production output and modernizing its 11 U.S. manufacturing plants with new automation and capital equipment, the home appliances maker said. Earlier this year, peer Carrier Global also said it planned to invest $1 billion over five years in the U.S. By the time the plan is complete, Louisville, Kentucky-headquartered GE Appliances said it will have invested $6.5 billion across its U.S. manufacturing plants and distribution network since it was acquired by Chinese consumer electronics major Haier from General Electric in 2016. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
